AN2 Therapeutics, Inc. (ANTX) insider trading

By person

14 insiders · 21 transactions

14.3×

Eric Easom holds 14.3 times base salary in stock. $8.64M of shares against $603.75K in salary for 2025.

Salary from the company's own proxy. The shares are what Eric Easom last reported holding, valued at $6.02, the price Common Stock was last bought or sold at on the open market here, on 9 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Robin Shane Readnour

Director

—

$316.70K (8) scheduled

−$316.70K

1,267,709

3.36%

$7.64M

+29.9%

Joshua M Eizen

See Remarks

—

$49.76K (3)

−$49.76K

206,554

0.5474%

$1.24M

+46.1%

Margaret M FitzPatrick

Director

$11.60K (1)

—

+$11.60K

10,708

0.0284%

$64.51K

—

Sanjay Chanda

Chief Development Officer

—

$9.33K (2)

−$9.33K

118,823

0.3149%

$715.83K

+177.7%

Lucy Day

Chief Financial Officer

—

$8.88K (2)

−$8.88K

118,363

0.3137%

$713.05K

+159.4%

Stephen David Prior

Chief Strategy Officer

—

$6.51K (2)

−$6.51K

59,086

0.1566%

$355.95K

+46.5%

Sarah Joanne Williams

Principal Accounting Officer

—

$3.02K (3)

−$3.02K

66,311

0.1757%

$399.48K

+252.7%

Braden Michael Leonard

10% owner

—

3,217,432

8.53%

$19.38M

−45.9%

Eric Easom

Chief Executive Officer

—

1,434,396

3.80%

$8.64M

+28.4%

Kabeer Aziz

Director

—

439,113

1.16%

$2.65M

+16.3%

Joseph S Zakrzewski

Director

—

145,538

0.3857%

$876.76K

−71.1%

Cameron C. Trenor III

Chief Medical Officer

—

116,667

0.3092%

$702.84K

—

Gilbert Lynn Marks

Director

—

84,156

0.2230%

$506.98K

+268.6%

Patricia A. Martin

Director

—

19,252

0.0510%

$115.98K

—

AN2 Therapeutics, Inc.

What the insiders did Net selling

By person